GTCbio is excited to announce the finalists for the inaugural new company/technology pitch competition at the CNS Diseases summit scheduled for Sep 11-12, 2017 in Boston. The following companies will compete for the “Most Promising New Technology” award and $5000 monetary prize.
- Orion BioScience – developing innovative therapies to cure autoimmune diseases using a soluble antigen array (‘SAgA’) platform technology.
- Cogentis Therapeutics –developing therapies that target the dysregulated cyclin-dependent kinase 5 (DK5) molecular pathway.
- Pro-Arc Diagnostics – developing blood tests for virulent and harmless John Cunningham Virus (JCV), which can cause fatal complications for patients taking powerful immunomodulatory drugs.
- NeuroLucent – developing a therapeutic for Alzheimer’s disease (AD) using RyR2, an intracellular Ca2+ transporter as a target for drug development
- Acelot –developing small molecules that reduce the toxic forms of Aβ oligomers before they lead to neurodegeneration in Alzheimer’s disease (AD).
Thank you to the following judges and moderator for helping us with this effort.
– Kevin Bitterman, Partner, Atlas Venture
– Christine Brennan, Partner, MRL Ventures Fund
– Ole Isacson, Professor of Neurology, Harvard Medical School
– Kiran Reddy, Partner, Clarus Ventures
– Barbara Tate, Venture Partner, Dementia Discovery Fund/SV Life Sciences
– Ginger Johnson, Vice President, Defined Health (Moderator)
We welcome you to join us at the 11th Annual CNS Diseases Summit, to be held on September 11-12, 2017 in Boston, MA.